Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their main product, Guardant360, is an FDA-approved test that helps healthcare providers make informed treatment decisions for patients with advanced cancer. The tests work by analyzing blood samples to detect and monitor cancer, allowing for non-invasive diagnostics. Unlike many competitors, Guardant Health focuses on providing data-rich insights that can guide treatment from early detection to advanced disease management. The company's goal is to enhance patient outcomes and lessen the impact of cancer through innovative diagnostic solutions.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2137.8M
Above
Industry Average
Funded Over
8 Rounds
Professional Development Budget
Performance Bonus
Guardant Health, a leading precision oncology company, has entered into a collaboration with ConcertAI, an oncology real-world evidence (RWD) data and AI technology company.
What You Should Know:– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.Enhanced Cancer Research and DevelopmentCancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression. Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread. Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies
PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).
NEW YORK - Guardant Health said Wednesday that it has entered into a collaboration with Boehringer Ingelheim to pursue regulatory approval and commercialization of its Guardant360 CDx liquid biopsy assay as a companion diagnostic for Boehringer's investigational drug zongertinib in lung cancer.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Find jobs on Simplify and start your career today